A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Merck Sharp & Dohme LLC
Pfizer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Rutgers, The State University of New Jersey
Pfizer
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Roswell Park Cancer Institute
Vejle Hospital
RemeGen Co., Ltd.
Institut du Cancer de Montpellier - Val d'Aurelle
UNICANCER
City of Hope Medical Center
First Affiliated Hospital of Guangxi Medical University
Ruijin Hospital
Institut Bergonié
IFOM ETS - The AIRC Institute of Molecular Oncology
First Affiliated Hospital of Guangxi Medical University
Memorial Sloan Kettering Cancer Center
Pfizer
City of Hope Medical Center
Baylor College of Medicine
NRG Oncology
NuCana plc
Charite University, Berlin, Germany
Memorial Sloan Kettering Cancer Center
Sun Yat-sen University
Sun Yat-sen University
Institut du Cancer de Montpellier - Val d'Aurelle
Ohio State University Comprehensive Cancer Center
Alliance for Clinical Trials in Oncology
Ohio State University Comprehensive Cancer Center
University of Kansas Medical Center
Rutgers, The State University of New Jersey
Peking Union Medical College Hospital
Fudan University
Fudan University
Medical University of Vienna
NSABP Foundation Inc
Asan Medical Center
GERCOR - Multidisciplinary Oncology Cooperative Group
Second Affiliated Hospital, School of Medicine, Zhejiang University
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
Barbara Ann Karmanos Cancer Institute
University of Roma La Sapienza
Sun Yat-sen University